Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q34106870)
Watch
English
JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo.
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMCID
4148771
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24957147%20AND%20SRC:MED&resulttype=core&format=json
retrieved
21 March 2020
title
JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo
(English)
1 reference
stated in
Europe PubMed Central
PMCID
4148771
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24957147%20AND%20SRC:MED&resulttype=core&format=json
retrieved
21 March 2020
main subject
ruxolitinib
1 reference
based on heuristic
inferred from title
author
Paolo Gallipoli
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMCID
4148771
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24957147%20AND%20SRC:MED&resulttype=core&format=json
retrieved
21 March 2020
Amy Cook
series ordinal
2
1 reference
stated in
Europe PubMed Central
PMCID
4148771
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24957147%20AND%20SRC:MED&resulttype=core&format=json
retrieved
21 March 2020
Susan Rhodes
series ordinal
3
1 reference
stated in
Europe PubMed Central
PMCID
4148771
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24957147%20AND%20SRC:MED&resulttype=core&format=json
retrieved
21 March 2020
Helen Wheadon
series ordinal
5
1 reference
stated in
Europe PubMed Central
PMCID
4148771
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24957147%20AND%20SRC:MED&resulttype=core&format=json
retrieved
21 March 2020
Anthony D Whetton
series ordinal
6
1 reference
stated in
Europe PubMed Central
PMCID
4148771
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24957147%20AND%20SRC:MED&resulttype=core&format=json
retrieved
21 March 2020
Heather G Jørgensen
series ordinal
7
1 reference
stated in
Europe PubMed Central
PMCID
4148771
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24957147%20AND%20SRC:MED&resulttype=core&format=json
retrieved
21 March 2020
Ravi Bhatia
series ordinal
8
1 reference
stated in
Europe PubMed Central
PMCID
4148771
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24957147%20AND%20SRC:MED&resulttype=core&format=json
retrieved
21 March 2020
Tessa Holyoake
series ordinal
9
1 reference
stated in
Europe PubMed Central
PMCID
4148771
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24957147%20AND%20SRC:MED&resulttype=core&format=json
retrieved
21 March 2020
author name string
Lisa Hopcroft
series ordinal
4
1 reference
stated in
Europe PubMed Central
PMCID
4148771
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24957147%20AND%20SRC:MED&resulttype=core&format=json
retrieved
21 March 2020
language of work or name
English
0 references
publication date
23 June 2014
1 reference
stated in
Europe PubMed Central
PMCID
4148771
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24957147%20AND%20SRC:MED&resulttype=core&format=json
retrieved
21 March 2020
published in
Blood
1 reference
stated in
Europe PubMed Central
PMCID
4148771
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24957147%20AND%20SRC:MED&resulttype=core&format=json
retrieved
21 March 2020
volume
124
1 reference
stated in
Europe PubMed Central
PMCID
4148771
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24957147%20AND%20SRC:MED&resulttype=core&format=json
retrieved
21 March 2020
issue
9
1 reference
stated in
Europe PubMed Central
PMCID
4148771
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24957147%20AND%20SRC:MED&resulttype=core&format=json
retrieved
21 March 2020
page(s)
1492-1501
1 reference
stated in
Europe PubMed Central
PMCID
4148771
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24957147%20AND%20SRC:MED&resulttype=core&format=json
retrieved
21 March 2020
cites work
Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
Important scaffold function of the Janus kinase 2 uncovered by a novel mouse model harboring a Jak2 activation-loop mutation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
Conditional deletion of Jak2 reveals an essential role in hematopoiesis throughout mouse ontogeny: implications for Jak2 inhibition in humans
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
ID1 promotes expansion and survival of primary erythroid cells and is a target of JAK2V617F-STAT5 signaling
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
Id1, but not Id3, directs long-term repopulating hematopoietic stem-cell maintenance
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
Id1 restrains myeloid commitment, maintaining the self-renewal capacity of hematopoietic stem cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
Janus kinase 2: a critical target in chronic myelogenous leukemia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
STAT5 signaling is required for the efficient induction and maintenance of CML in mice
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
Jak2 is involved in c-Myc induction by Bcr-Abl
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
The NH(2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
The Jak-Stat pathway in normal and perturbed hematopoiesis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: role of malignant stromal macrophages.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
5 July 2018
Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
28 October 2018
The IL-2/CD25 axis maintains distinct subsets of chronic myeloid leukemia-initiating cells.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
28 October 2018
Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348).
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
28 October 2018
High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
28 October 2018
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
28 October 2018
beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
28 October 2018
Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
28 October 2018
The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148771
retrieved
28 October 2018
Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/24957147
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/24957147
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.1182/BLOOD-2013-12-545640
1 reference
stated in
Europe PubMed Central
PMCID
4148771
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24957147%20AND%20SRC:MED&resulttype=core&format=json
retrieved
21 March 2020
PMCID
4148771
1 reference
stated in
Europe PubMed Central
PMCID
4148771
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24957147%20AND%20SRC:MED&resulttype=core&format=json
retrieved
21 March 2020
PubMed ID
24957147
1 reference
stated in
Europe PubMed Central
PMCID
4148771
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24957147%20AND%20SRC:MED&resulttype=core&format=json
retrieved
21 March 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit